Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mircera EPO Will Benefit From Lower Admin Costs Of Monthly Dosing – Roche

Executive Summary

Monthly dosing for Roche's continuous erythropoietin receptor activator Mircera may make it attractive to providers because of the lower costs of administration associated with the extended dosing regimens, according to Pharmaceutical Division CEO William Burns

You may also be interested in...



Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data

Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator

Amgen On The Offensive Against Roche’s EPO Mircera; Questions Safety Data

Amgen is continuing its offensive against Roche's pending EPO product Mircera by signing an exclusive supply contract with a large dialysis provider and criticizing Roche's clinical trial program for the continuous erythropoietin receptor activator

Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off

After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel